4Cl-iBF Stats & Data
CC(C)C(=O)N(C1CCN(CCc2ccccc2)CC1)c1ccc(Cl)cc1YWHLYGSHOQKCJG-UHFFFAOYSA-NEffect Profile
CuratedStrong euphoria and pain relief with strong itching/nausea, low sedation
Tolerance & Pharmacokinetics
drugs.wikiNo tolerance chart. Our decay curves for opioids were estimates, and a curve can make tolerance look longer-lasting than it is, which is the dangerous direction.
Opioid tolerance drops fast when you stop, and even a few days off can be enough, so a dose that used to be normal can now stop your breathing. Overdose deaths rise sharply after prison, detox or leaving treatment, and tolerance also falls during a hospital stay. After any break, start with a much smaller amount, try a test dose first, don't use alone, and keep naloxone within reach. Alcohol, benzodiazepines, gabapentinoids and other sedatives make an opioid overdose much more likely.
Sources: FRANK: heroin · National Harm Reduction Coalition · WHO: opioid overdose · Merrall et al. 2010 · Binswanger et al. 2007 · Strang et al. 2003 · FDA 2019: gabapentinoids and breathing
Cross-Tolerances
Harm Reduction
drugs.wiki• Extreme potency: doses are in micrograms. Consumer‑grade 0.001 g (1 mg) scales are not reliable at this range; even 0.1 mg readability devices may be inaccurate. Use volumetric dosing: dissolve a known mass into a measured volume and measure doses by volume; label concentrations. Never eyeball powder.
• Combining with other depressants (alcohol, benzodiazepines, Z‑drugs, GHB/GBL) markedly raises the risk of fatal respiratory depression; avoid these combinations.
• Gabapentin/pregabalin with opioids increases overdose and respiratory‑depression risk in population studies; avoid or use only under medical oversight.
• Tramadol with opioids increases seizure and serotonin‑toxicity risk; combination is unsafe.
• DXM with opioids is considered a dangerous combo (additive CNS depression and other risks).
• MAOIs should be avoided for at least 14 days; caution with SSRIs/SNRIs due to rare but reported serotonin toxicity with fentanyl.
• Rapid IV bolus of fentanyl‑class drugs can precipitate chest‑wall rigidity and difficult ventilation; if someone injects despite risks, slow, incremental administration reduces (but does not eliminate) risk.
• Naloxone reverses toxicity but may require repeated doses or infusion for potent/longer‑acting opioids; always call emergency services and monitor after reversal.
• Test strips: common FTS detect fentanyl and certain analogues but not all; they give a binary result and cannot quantify potency. A negative does not guarantee safety; a positive does not reveal which analogue.
• Unregulated opioid samples often contain benzodiazepine‑related drugs or ultra‑potent opioids (e.g., nitazenes), massively increasing overdose risk. Do not use alone; have naloxone present and a trained observer.
• Safer‑use injection practices (if used): sterile equipment, use a needle/syringe program, rotate sites, and seek medical care early for infections.
• Oral (swallowed) fentanyl has low bioavailability; clinically, transmucosal routes are used for fentanyl. By analogy, sublingual/buccal routes for some analogues may have higher efficiency than swallowing, but individual kinetics for 4Cl‑iBF are unknown—start low and avoid redosing during the first hour.
• Overdose recognition: unresponsive, slow/shallow or stopped breathing, blue lips, pinpoint pupils. Call emergency services immediately; place in recovery position and administer naloxone if available.
References
Cited references
- EUDA Spotlight — Fentanils and other new opioids (overview of risks, potency, overdose)
- DrugChecking Community — Fentanyl test strips limitations (BTNX strips; binary, cross‑reactivity with some analogues only)
- DrugChecking Community — Fentanyl test strips FAQ/overview (qualitative result, not all analogues, cannot quantify)
- StatPearls — Opioid Anesthesia (opioid‑induced chest‑wall rigidity; MAOI caution; SSRIs/SNRIs)
- WHO Model Formulary annex (fentanyl injection precautions; avoid rapid injection due to rigidity)
- StatPearls — Naloxone (need for repeated dosing/infusion with potent/longer‑acting opioids)
- CADTH/NCBI — Naloxone PK and short half‑life (re‑sedation risk after reversal)
- NCBI Bookshelf — Opioid Toxicity (co‑ingestants, respiratory arrest primary cause)
- DrugBank — Fentanyl monograph (avoid alcohol/benzodiazepines; transmucosal PK)
- Therapeutics Letter/NCBI — Gabapentinoids can cause severe respiratory depression; warnings and evidence review
- AHRQ/NCBI — Opioid + gabapentinoid co‑prescribing associated with higher overdose risk (observational studies)
- DrugBank — Tramadol (SNRI properties, seizure and serotonin‑syndrome risk; avoid with other opioids)
- TripSit — Drug combinations (dangerous: opioids + DXM; opioids + alcohol/benzodiazepines; tramadol + opioids)
- TripSit — Volumetric dosing tool (practical calculator and guidance)
- Drug Users Bible — Microgram/milligram weighing limits and volumetric dosing rationale
- DrugChecking Community — Toronto’s Drug Checking Service reports (benzos and ultra‑potent opioids co‑present with fentanyl)
- DrugChecking Community — Ultra‑potent opioids alert (carfentanil/nitazenes in supply)
- DrugWise — Overdose recognition (signs; depressant mixing risk)
- DrugWise — Needle exchanges (sterile equipment; naloxone access)